$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Biosimilars and the need for a policy prescription
Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...
Armed robbery in Revesby7d
Biosimilars Boost Access to Key Biologic Treatments
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
pharmaphorum8d
Its Herceptin biosimilar nearing launch, Celltrion begins work on Keytruda copy
While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...
The American Journal of Managed Care29d
Biosimilar Market Share: Growth and Price Trends in Q1 2025
The Q1 2025 biosimilar ASP discounts averaged 52% for trastuzumab, 49% for bevacizumab, and 66% for rituximab markets. The WAC discounts for supportive care biosimilars are between 18% and 67% ...
Clarity Pharmaceuticals expands breast cancer pipeline with 64/67Cu-SAR-trastuzumab
Clarity Pharmaceuticals has added 64/67Cu-SAR-trastuzumab to its Targeted Copper Theranostic (TCT) portfolio, strengthening ...
Business Wire15d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac ® in Europe), a ...